Abstracts tagged "race/ethnicity"

Abstract Number: 0999 • ACR Convergence 2023
Race, Payer, and Hospital Factors Are Associated with Post-primary Total Hip Arthroplasty Healthcare Utilization
Kranti Rumalla¹, Sumanth Chandrupatla² and Jasvinder Singh², ¹Northwestern School of Medicine, Chicago, IL, ²University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Over 450,000 primary total hip arthroplasties (THA) are performed each year. One major indication for primary THA is the presence of osteoarthritis (OA). Patient…
Abstract Number: 1952 • ACR Convergence 2023
Anti-MDA5 Associated Dermatomyositis: Clinical Features and Outcomes in a Predominantly African-American Case Series
David Wang¹, Arezou Khosroshahi² and Prateek Gandiga², ¹Emory University School of Medicine, Atlanta, GA, ²Emory University, Atlanta, GA
Background/Purpose: Individuals with autoantibodies against melanoma differentiation-associated protein 5 (MDA-5) are reported to have a significant risk of developing rapidly progressive and fatal interstitial lung…
Abstract Number: 1014 • ACR Convergence 2023
Rheumatic Immune-Related Adverse Events Following Immune Checkpoint Inhibitor Therapy and Subsequent Referrals to Rheumatologists at a Private vs Public Medical Center in Los Angeles: Ramifications for Health Disparities
Laura Kobashigawa¹, Nicole Zagelbaum², Katherine Ruddy³, Martha Delgado¹, Baljeet Rai⁴, Victoria Gevorgyan⁵, Kiana Mortezaei⁶, William Stohl⁷ and Elizabeth Taylor-Albert MD⁸, ¹LAC+USC Internal Medicine Residency, Los Angeles, CA, ²Beverly Hills Arthritis Associates, Beverly Hills, CA, ³LAC+USC Internal Medicine Residency, Los Angeles, MD, ⁴University of California San Francisco, San Francisco, CA, ⁵Los Angeles County Hospital, Los Angeles, CA, ⁶Keck Medical Center of USC, Los Angeles, CA, ⁷University of Southern California Keck School of Medicine, Division of Rheumatology, Los Angeles, CA, ⁸University of Southern California, Santa Monica, CA
Background/Purpose: Immune checkpoint inhibitors (ICIs) represent a breakthrough in cancer therapies. However, ICIs may be associated with significant immune-related adverse events (irAEs), including rheumatic irAEs.…
Abstract Number: 2087 • ACR Convergence 2023
Racial and Ethnic Diversity in Pediatric Fellowships: Fortifying the Pipeline
Bessie Roca Loor¹, Maya Pandit², Tracey Wright³ and Mill Etienne⁴, ¹New York Medical College, Yonkers, NY, ²Columbia University, New York, NY, ³UT Southwestern, Dallas, TX, ⁴New York Medical College, Valhalla, NY
Background/Purpose: The 2015 American College of Rheumatology Workforce study estimated the pediatric rheumatology full-time equivalent workforce to be 300 providers while the estimated excess demand…
Abstract Number: 0149 • ACR Convergence 2023
Impacts of Social Determinants of Health and the Immune System in Adults with Acute-to-Chronic Low Back Pain: An Observational Study
Colleen Burke¹, Michael Brown², Kenneth Taylor², Stephanie Danyluk², Kelley Seebeck² and Adam Goode³, ¹Duke University School of Medicine, Chapel Hill, NC, ²Duke University School of Medicine, Durham, NC, ³Duke University, Durham, NC
Background/Purpose: Chronic low back pain (cLBP) is common worldwide yet poorly understood due to the combination of biological, psychological, and sociological factors. An individual's social…
Abstract Number: 1024 • ACR Convergence 2023
Relationship Between Race and Ethnicity, Time to Diagnosis, and Disease Activity for Children with Juvenile Idiopathic Arthritis in the CARRA Registry
Sarah McGuire¹, Tania Atanassova², Joanna Madej², Manuel Jimenez², Daniel Horton¹ and for the CARRA TMJ Arthritis Workgroup³, ¹Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ²Rutgers, Robert Wood Johnson Medical School, New Brunswick, NJ, ³Childhood Arthritis and Rheumatology Research Alliance, Washington, DC
Background/Purpose: Compared to non-Hispanic White children, Black children diagnosed with juvenile idiopathic arthritis (JIA) have more severe disease at diagnosis and worse outcomes, such as…
Abstract Number: 2088 • ACR Convergence 2023
Room for Racial and Ethnic Diversity in Adult Rheumatology Fellowship Pipeline
Bessie Roca Loor¹, Maya Pandit², Tracey Wright³ and Mill Etienne⁴, ¹New York Medical College, Yonkers, NY, ²Columbia University, New York, NY, ³UT Southwestern, Dallas, TX, ⁴New York Medical College, Valhalla, NY
Background/Purpose: The 2015 American College of Rheumatology Workforce study showed 8 of 1011 adult rheumatologists identified as Black, 85 Hispanic and 3 American Indian or…
Abstract Number: 0153 • ACR Convergence 2023
Diminished Vibration Perception and Greater Pressure Pain Sensitivity Are Associated with Worse Knee Osteoarthritis Outcomes Across Sex and Race
Chris Lane¹, Louise Thoma², Carolina Alvarez³, Deborah Givens⁴, Amanda Nelson⁴, Adam Goode⁵, Kharma Foucher⁶ and Yvonne Golightly⁷, ¹UNC Chapel Hill, Chapel Hill, NC, ²University of North Carolina, Chapel Hill, NC, ³University of North Carolina at Chapel Hill, Miami, FL, ⁴University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁵Duke University, Durham, NC, ⁶University of Illinois at Chicago, Chicago, IL, ⁷University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Sex and race differences have been observed in clinical outcomes such as patient-reported pain and function in adults with knee OA. However, few studies…
Abstract Number: 1025 • ACR Convergence 2023
Embedding Treat to Target Principles in Rheumatoid Arthritis Patient Education in Routine Care of Ethnic Minority Patients
Sharon Dowell¹, Mercedes Quinones², Tahereh Jamshidi³, Ilona Jileaeva⁴, Oshoze Kadiri⁴ and Gail Kerr⁵, ¹NEA Baptist Memorial Hospital, Jonesboro, AR, ²Washington DC VA Medical Center, Bethesda, MD, ³Howard University Hospital, Bethesda, MD, ⁴Howard University, Washington, DC, ⁵Washington DC VAMC/Georgetown and Howard Universities, Washington, DC
Background/Purpose: A successful treat to target (T2T) strategy in ethnic minority (EM) patients with rheumatoid arthritis (RA) could improve patient outcomes and help reduce healthcare…
Abstract Number: 2347 • ACR Convergence 2023
Efficacy of Belimumab in Patients with Systemic Lupus Erythematosus by Race and Ethnicity: A Large Post Hoc Integrated Analysis of Five Clinical Trials
Saira Sheikh¹, Amit Saxena², Angela Carroll³, Christine Henning³, Julia HN Harris⁴, Bernard Rubin⁵, David D'Cruz⁶ and Alvin F Wells⁷, ¹University of North Carolina at Chapel Hill, Chapel Hill, NC, ²New York University Grossman School of Medicine, Rheumatology, New York, NY, ³GlaxoSmithKline, US Medical Affairs, Durham, NC, ⁴GlaxoSmithKline, Immunology Biostatistics, Brentford, United Kingdom, ⁵GlaxoSmithKline, US Medical Affairs and Immuno-inflammation, Durham, NC, ⁶Guy’s Hospital, Louise Coote Lupus Unit, London, United Kingdom, ⁷Advocate Health Department of Rheumatology, Franklin, WI
Background/Purpose: Belimumab (BEL) is approved for the treatment of active SLE, and lupus nephritis, with standard therapy.1 The prevalence and severity of SLE tend to…
Abstract Number: 0177 • ACR Convergence 2023
Cost-Related Medication Non-Adherence Among US Adults with Chronic Arthritis: Trends, Comparisons, and Disparities
Ashkan Ara¹, Matthew Chenoweth¹, Christopher Scannell² and John FitzGerald¹, ¹University of California Los Angeles, Los Angeles, CA, ²UCLA / West Los Angeles VA Medical Center, Los Angeles, CA
Background/Purpose: Cost-related medication non-adherence (CRN), a measure of drug affordability, refers to a patient's inability to adhere to a prescribed medication regimen due to high…
Abstract Number: 1030 • ACR Convergence 2023
Patterns in the Prescription, the Denials of Coverage, and the Delays in Dispensation of Janus Kinase Inhibitors
Thomas Riley¹, Igor Dombrovsky², Michael George³ and Joshua Baker³, ¹Hopsital of the University of Pennsylvania, Springfield, PA, ²Pennsylvania Hospital, Philadelphia, PA, ³University of Pennsylvania, Philadelphia, PA
Background/Purpose: Janus kinase inhibitors (JAKi) have therapeutic benefits in autoimmune conditions. Access to these medications is controlled by insurance carriers through requirements for prior authorizations…
Abstract Number: 2459 • ACR Convergence 2023
Reporting of Race and Ethnicity in Lupus Publications in High-impact Rheumatology Journals
Idil Eroglu, Hailey Baker, Mario Felix and Lisa Suter, Yale School of Medicine, New Haven, CT
Background/Purpose: Reporting of race and ethnicity as social constructs is critical to highlight equity and diversity of study participants, with the knowledge that socio-economic factors…
Abstract Number: 0178 • ACR Convergence 2023
Traditional and Lupus-Specific Risk Factors for Cardiovascular Events Among Patients with Systemic Lupus Erythematosus
Saloni Patolia, Dulaney Wilson, Jim Oates and Diane L. Kamen, Medical University of South Carolina, Charleston, SC
Background/Purpose: Even among young women with systemic lupus erythematosus (SLE), accelerated atherosclerosis and coronary artery disease are common complications. Traditional risk scoring methods underestimate cardiovascular…
Abstract Number: 1032 • ACR Convergence 2023
“Not of Your Ethnicity”: A Qualitative Study Exploring Diverse Patient Experiences in Axial Spondyloarthritis (axSpA)
Bryanna Mantilla¹, K Wysham², Jean liew³ and Grant Hughes¹, ¹University of Washington, Seattle, WA, ²VA Puget Sound/University of Washington, Seattle, WA, ³Boston University, Boston, MA
Background/Purpose: Axial spondyloarthritis (axSpA) can result in significant morbidity. Existing studies suggest functional impairment and inflammation may be worse in Black and Latine patients. However,…

« Previous Page
1
…
3
4
5
6
7
…
14
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].